On February 13, 2025, Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, announced the closing of an oversubscribed $93.5 million Series A financing. The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. Wilson Sonsini advised Novo Holdings A/S on the transaction.

Newleos Therapeutics is dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next-generation, first- and best-in-class therapies. The company’s clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders, and cognitive impairment.

The Wilson Sonsini team that advised Novo Holdings on the transaction includes:

Corporate
Dan Koeppen
Kassandra Castillo
James Keegan

Patents and Innovations
Maya Skubatch
Ying Chen

Technology Transactions
Nguyen Pham

For more information, please see Newleos’ press release.